Protalix BioTherapeutics (PLX) PT Raised to $2.10 at Jefferies; Funding Risk Removed
Tweet Send to a Friend
Jefferies raised its price target on Protalix BioTherapeutics (NYSE: PLX) to $2.10 (from $1.80) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
